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Abstract
As transcriptional regulators, circadian genes have the potential to influence a variety of biological
pathways, including many cancer-related processes. Cryptochrome 2 (CRY2) is essential for
proper circadian timing, and is a key component of the circadian regulatory feedback loop. Here,
we report findings from genetic, epigenetic, loss-of-function, and transcriptional profiling analyses
of CRY2 in breast cancer. Six SNPs in CRY2 were identified for genotyping in a case-control
population (N=441 cases and N=479 controls), and three SNPs (rs11038689, rs7123390, and
rs1401417) were significantly associated with postmenopausal breast cancer risk, with significant
effect modification by menopausal status (dominant model for rs11038689: odds ratio (OR) =
0.71, 95% confidence interval (CI): 0.51–0.99, P for trend = 0.028; homozygous variants for
rs7123390: OR = 0.44, 95% CI: 0.22–0.86, P for trend = 0.028; and rs1401417, OR=0.44, 95%
CI: 0.21–0.92, P for trend = 0.017). Interestingly, this association was only evident in women with
estrogen and progesterone receptor (ER/PR) negative breast tumors, but not with ER/PR positive
tumors. Breast cancer patients also had significantly higher levels of CRY2 promoter methylation
relative to controls, which is consistent with tissue array data showing lower levels of CRY2
expression in tumor tissue relative to adjacent normal tissue. Furthermore, in vitro analyses
identified a number of breast cancer-relevant genes which displayed altered expression following
CRY2 knockdown. These findings suggest a role for CRY2 in breast tumorigenesis, and provide
further evidence that the circadian system may be an important modulator of hormone-related
cancer susceptibility.
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Introduction
The human circadian rhythm is a fundamental aspect of human physiology, and a wide
range of biological processes are influenced by the circadian clock, including body
temperature, energy metabolism, hormone secretion, and sleep-wake cycles (1). Circadian
disruption is associated with a variety of adverse affects including metabolic disruption, the
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promotion of oxidative stress, and alterations in immune function (2). Increasing evidence
also suggests that the circadian system may play a critical role in various cancer-related
processes (3, 4), and the International Agency for Research on Cancer (IARC) recently
concluded that shift work that involves circadian disruption is “probably carcinogenic to
humans” (5).
At the molecular level, the maintenance of circadian rhythm involves a complicated
interplay between environmental and endogenous cues, and many circadian processes are
regulated by a relatively small set of core circadian genes (6). These genes form a negative
and positive feedback system, which allows for fairly tight control of circadian gene
expression, thereby ensuring that circadian gene products will be active during the
appropriate phase of the circadian cycle (7–9). Recent evidence indicates that several of the
core circadian genes are involved in transcriptional regulation, and as many as 2–10% of all
mammalian genes may be regulated to some degree by the circadian oscillatory mechanism,
suggesting the potential for broad consequences of disruptions to this system (10–12).
One such core circadian gene, CRY2, is essential to the maintenance of circadian rhythm
through its role in the negative arm of the feedback loop, and may function more broadly as
a transcriptional repressor (13–17). CRY2 has also been shown to be involved in cellular
proliferation, including roles in DNA damage checkpoint control (18) and regulation of
genes important for cell cycle progression (19, 20). The role of cryptochromes in DNA
damage response and susceptibility to carcinogenesis remains controversial, however, as
Cry1−/−, Cry2−/− transgenic mice did not display a cancer-prone phenotype in response to
ionizing radiation exposure (19). Here, we report findings from genetic and epigenetic
epidemiological analyses of CRY2 in breast cancer, as well as a loss-of-function
investigation into the effects of CRY2 knockdown on breast cancer-relevant gene expression.
Materials and Methods
Study subjects
The study population consists of subjects enrolled in a previous breast cancer case-control
study conducted in Connecticut. Details regarding subject recruitment and participant
characteristics have been described in previous publications (21, 22). Briefly, cases were
incident, histologically confirmed breast cancer patients (International Classification of
Diseases for Oncology, 174.0 –174.9) between the ages of 30 and 80 with no previous
diagnosis of cancer other than non-melanoma skin cancer, who were alive at the time of the
interview. Cases were either identified from computerized patient information at Yale-New
Haven Hospital (YNHH) in New Haven County, Connecticut, or from nearby Tolland
County, Connecticut via hospital records by the Rapid Case Ascertainment Shared Resource
at the Yale Cancer Center. YNHH controls were patients at YNHH who underwent breast-
related surgery for histologically confirmed benign breast diseases. Tolland county controls
were identified either through random digit dialing (for subjects younger than 65), or
through the Health Care Finance Administration files (for subjects age 65 and older). After
obtaining approval from each participant’s hospital and physician, potential subjects were
contacted by letter and then by telephone, and those who agreed to participate were
interviewed by a trained interviewer. Among YNHH subjects, participation rates were 71%
for controls and 77% for cases, and among Tolland County subjects, participation rates were
61% for controls and 74% for cases. A standardized, structured questionnaire was used to
obtain a number of participant characteristics including family history of cancer,
reproductive history, diet, and demographic factors. At the conclusion of the interview,
blood was drawn into sodium-heparinized tubes and DNA was isolated from peripheral
blood lymphocytes (PBLs) for use in genotyping and methylation analyses. ER and PR
status were determined immunohistochemically at YNHH, as previously described (23),
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with an H-score greater than 75 considered receptor positive. A total of 441 cases (93%) and
479 controls (95%) had DNA samples available for genetic analysis in the current study.
The mean age of cases was 57, while controls had a mean age of 55. Both cases and controls
were predominantly Caucasian (91% and 92%, respectively) with very few African
Americans (6% and 6%) or other races (3% and 2%). With the exception of menopausal
status (cases were 76.6% post-menopausal, compared to 65.6% in controls; P<0.001), no
measured factor differed significantly by case-control status.
SNP selection and genotyping
SNPs were identified in the Haploview interface of the HapMap genome browser, Release
22 (http://www.hapmap.org/cgi-perl/gbrowse/hapmap22_B36), using the Tagger algorithm
(24). Applying the pairwise tagging approach, which provides a list of the minimum number
of SNPs which can represent all of the markers in a given region at a specified level of
correlation, five SNPs (rs11038689, rs7123390, rs2292912, rs10838524, and rs11605924)
with minor allele frequencies greater than 0.1 were identified as representative of all
variation found within the exonic and intronic regions of the CRY2 gene with r2 ≥ 0.8. One
additional intronic SNP (rs1401417) which had been previously identified as significantly
associated with prostate cancer risk (25) was also included in the genotyping pool.
Genotyping for all SNPs was performed at Yale University’s W.M. Keck Foundation
Biotechnology Research Laboratory using the Sequenom MassARRAY multiplex
genotyping platform (Sequenom, Inc., San Diego, CA) according to the manufacturer’s
protocol. Duplicate samples from 100 study subjects and 40 replicate samples from each of
two blood donors were interspersed throughout each batch for all genotyping assays. The
concordance rates for QC samples were over 95% for all assays. All genotyping calls,
including quality control data, were re-checked by different laboratory personnel and
genotyping scores were reproduced with 100% accuracy.
CpG island identification and methylation analysis
Using the CpG Island Searcher web tool (http://www.cpgislands.com/), one CpG island was
identified that spans the promoter region, the first exon, and part of the first intron of the
CRY2 gene (−450 to +750). The MethPrimer program (www.urogene.org//methprimer) was
then used to design methylation specific PCR primers within the identified CpG island
region. To distinguish methylated and unmethylated DNA sequences, genomic DNA
samples isolated from PBLs were bisulfite treated using the EZ DNA Methylation Kit
(Zymo Research, Orange, CA) according to the manufacturer’s protocol. Upon bisulfite
treatment, unmethylated cytosines are converted into uracil whereas methylated cytosines
remain unchanged. After the conversion, the presence of methylation was determined by
quantitative PCR using primers specific to the methylated or unmethylated sequence, and
the Power SYBR Green Kit (Applied Biosystems) according to the manufacturer’s protocol.
The primer sequences used to detect unmethylated DNA were L:
GTTTGTGGATAGTTTTAGTTTGT and R: CACCTAACAATTAACCCAAAAACA, and
the primers for methylated DNA were L: GTTTGCGGATAGTTTTAGTTTGC R:
CCTAACGATTAACCCAAAAACG. A methylation index was determined for each subject
using the following formula: MI = [1 / (1+2−(CTu-CTme)] × 100%, as previously described
(26), where CTu = the average cycle threshold obtained from duplicate qPCRs using the
unmethylated primers, and CTme = the average cycle threshold obtained using the
methylated primers. Since radio- and chemotherapy can affect DNA methylation, only
patients from the breast cancer population who had not undergone these treatments were
included in this portion of the analysis (n=80), along with an equal number of age-matched
controls. Each PCR reaction was performed in duplicate using both the unmethylated and
methylated primers, for a total of four reactions per subject. One or more of these reactions
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failed (no amplification or standard deviation greater than 1 across replicates) in samples
from four of the cases, and were thus excluded, leaving a final sample of 76 cases and 80
controls.
Cell culture and treatments
Human breast adenocarcinoma cells (MCF-7) were obtained from American Type Culture
Collection (Manassas, VA). Cells were maintained in Dulbecco’s modified Eagle medium
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen), 0.01
mg/ml bovine insulin, and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO).
siRNA oligos targeting CRY2 (Sense: 5’-UGCUUCAUUCGUUCAAUGUUAAGCCGG-3’
Antisense: 5’-GGCUUAACAUUGAACGAAUGAAGCA-3’) and a scrambled sequence
negative control siRNA (Sense: 5’-CUUCCUCUCUUUCUCUCCCUUGUGA-3’,
Antisense: 5’-UCACAAGGGAGAGAAAGAGGGAAGGA-3’) were designed and
manufactured by Integrated DNA Technologies (IDT, Coralville, IA). Each oligo was
diluted in OPTI-MEM serum-free medium (Invitrogen), complexed with Lipofectamine
RNAiMax transfection reagent (Invitrogen), and reverse transfected with approximately
100,000 cells in 12 well plates at a final concentration of 10nM. 48 hours after transfection,
cells were harvested and RNA was isolated for determination of CRY2 knockdown and
subsequent whole genome expression microarray.
RNA isolation, knockdown assessment, and whole genome expression microarray
RNA was extracted from cells treated with negative control and CRY2-targeting siRNA
oligos using the RNA Mini Kit (Qiagen, Valencia, CA), with on-column DNA digestion,
according to the manufacturer’s instructions for mammalian cells. The purified RNA was
then used as a template for first-strand cDNA synthesis using the AffinityScript cDNA kit
(Stratagene, La Jolla, CA) with oligo-dT primers. Quantitative real-time PCR was
performed using the Power SYBR Green PCR master mix (Applied BioSystems, Foster
City, CA) with gene-specific primers, and a standard thermal cycling procedure on an ABI
7500 instrument (Applied BioSystems). The primers used for CRY2 amplification were: (L:
ACCGGGGACTCTGTCTACTG, R: GCCTGCACTGCTCATGCT). RNA quantity was
normalized using HPRT1 content, and CRY2 silencing was quantified according to the
2−ΔΔCt method. Biological replicates of RNA extracted from CRY2 knockdown and normal
cells were interrogated by whole genome microarray (Agilent, Inc 44k chip, performed by
MoGene, LC, St Louis, MO). All microarray data has been uploaded to the Gene Expression
Omnibus (GEO) database, and this data can be accessed by referencing accession
#GSE14617. As the focus of the current study was on breast cancer and hormone signaling,
we performed a search for breast cancer-related genes using two online resources: The
Breast Cancer & Estrogen Receptor Signaling pathway gene list from SABiosciences
(cat#PAHS-005), and the hormone-related genes identified by the Breast and Prostate
Cancer Cohort Consortium (http://epi.grants.cancer.gov/BPC3/gene.html) in order to
compile a targeted list of transcripts for analysis.
Expression analysis of CRY2 in breast tumor tissues
We searched the Array Express database (27) (www.ebi.ac.uk/arrayexpress) using the Atlas
of Gene Expression function to identify an expression array comparison involving breast
tumor tissue and adjacent normal tissue. Using the keywords: Gene, “CRY2”; Conditions,
“Breast Cancer”; and setting the species filter to Homo Sapiens, one array was identified
(accession number E-TABM-276). The investigators of this study collected samples from
breast tumors, and the surrounding zones (1cm, 2cm, 3 cm and 4 cm away from the
boundary of the tumor) (28). For the current analysis, we focused on patients for which
expression data was available for both tumor samples and distant normal tissue (3–4cm
away), and conducted a paired analysis of CRY2 expression levels. Further details regarding
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tissue collection and the experimental protocol of this array are available at the Array
Express database, or from the primary publication (28).
Statistical analysis
All statistical analyses were performed using the SAS statistical software, version 9.1 (SAS
Institute, Cary, NC). CRY2 knockdown was assessed using the 2−ΔΔCt method with RNA
content normalized to the housekeeping gene HPRT1. For the case-control analyses, allelic
distributions for all SNPs were tested by goodness-of-fit chi-square for compliance with
Hardy-Weinberg equilibrium (HWE). Odds ratios and 95% confidence intervals were
determined for each disease associations by unconditional multivariate logistic regression.
Covariates included in the final model were: age (continuous), race (Caucasian, African-
American, Other), family history of breast cancer in a first-degree relative (no or yes; in
mother, sister, or daughter), BMI (<21, 21–24.9, 25+ kg/m2), smoking (ever or never),
family income per person 10 years prior to diagnosis or interview (<$20,000, $20,000–
24,999, $25,000+, or unknown), age at menarche (<13, 13–14, 15+ years), lifetime months
of lactation (0, 1–10, 11+), number of live births (0, 1–3, 4+), and study site (New Haven
County or Tolland County). Information on hormone use was not available for this
population and thus could not be controlled for. Other factors, including alcohol
consumption and age at first birth did not influence the effect estimates and were thus
excluded from the final models. An interaction term was added to the model and the P-value
associated with the Wald test comparing the parameter estimates for each association in pre-
and post-menopausal women was used to assess whether the effect of each SNP was
modified by menopausal status. Haplotypes were determined using the PHASE program
(29), and haplotypes with a frequency of less than 3% were not individually analyzed, but
were maintained in the analysis population as controls. Of the 12 haplotypes identified, 98%
of the sample chromosomes came from the 4 most frequent haplotypes, which were then
analyzed by unconditional multivariate logistic regression, using all other haplotypes as the
comparison group, and including the same group of covariates as the main effects models.
The sign rank test was used for comparison of CRY2 expression in paired samples of tumor
tissue and adjacent normal tissue, and expression level by ER/PR status was compared using
the Wilcoxon two-sample test. Due to the multiple comparisons involved in the microarray
analysis, adjustments were made to control for false positive findings. A correction was
applied to each observation using the Benjamini-Hochberg false discovery rate adjustment,
as previously described (30), to obtain a new adjusted P-value (Q).
Results
SNPs in CRY2 are associated with postmenopausal breast cancer risk
Six SNPs were identified for genotyping, including five internal tagging SNPs identified
through HaploView, and one SNP which had previously been identified as significantly
associated with prostate cancer risk (25). Genotyping failed for one SNP (rs10838524),
which was thus excluded from further analysis. For each of the five remaining SNPs,
compliance with Hardy-Weinberg equilibrium was examined among the controls, and no
significant departures were observed (P<0.10). Odds ratios and confidence intervals were
determined for each of the five remaining SNPs. A test of homogeneity indicated significant
(P<0.05) effect modification by menopausal status for three of these SNPs when comparing
homozygous genotypes. As such, overall associations are stratified by menopausal status.
For the three SNPs for which menopausal status was an effect modifier, significant
associations were observed with post-menopausal breast cancer risk (rs11038689: dominant
model odds ratio (OR)=0.71, 95% confidence interval (CI):0.51–0.99, rs7123390:
homozygous variant OR=0.44, 95% CI:0.22–0.86, rs1401417: homozygous variant
OR=0.44, 95% CI:0.21–0.92) (Table 1). A haplotype analysis of the five variants
Hoffman et al. Page 5
Cancer Prev Res (Phila). Author manuscript; available in PMC 2011 September 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
demonstrated that only one haplotype, that containing the three significant variants from the
main effects model, was significantly associated with breast cancer risk in postmenopausal
women (frequency=22.5%; OR=0.72, 95% CI:0.56–0.94), while no haplotypes were
significantly associated with pre-menopausal breast cancer (data not shown). Note that
despite the fact that each SNP was chosen using the haplotype-based Tagger algorithm (24),
we found significant correlation among the three significant SNPs (Supplementary Table 1).
As such, each of these SNPs may be serving as markers for the same causal SNP, and
therefore the three significant associations may be interpreted as approximating one single
association.
In an attempt to further explore these associations in a separate population, we also analyzed
a genome-wide association study (GWAS) of post-menopausal breast cancer initiated by
NCI’s Division of Cancer Epidemiology and Genetics (DCEG) in collaboration with the
Nurses’ Health Study (31). This dataset (available at: http://cgems.cancer.gov/data/), termed
the Cancer Genetic Markers of Susceptibility (CGEMS) study, contains four markers within
the genomic region of CRY2. None of these markers are significantly associated with breast
cancer risk in this population. However, only one of the four markers, rs11605924, was also
included in our study. The CGEMS estimated odds ratio for homozygotes (1.02), was
similar to our estimate among post-menopausal women (1.22), and both found no significant
association with breast cancer risk. In addition, the minor allele frequency (MAF) among the
controls for this SNP matches very closely with the MAF among controls in our population
(46.5% and 46.4%, respectively).
Association of CRY2 and postmenopausal breast cancer risk by hormone receptor status
Since estrogen and progesterone receptor (ER/PR) status is an important clinical factor in
predicting breast cancer prognosis and dictating treatment options, we performed a separate
analysis of each SNP with the population stratified according to joint estrogen and
progesterone receptor status, where known. Interestingly, the homozygous or combined
heterozygous/homozygous variant genotypes for four of the five SNPs (rs11038689,
rs11605924, rs7123390, and rs1401417) were significantly associated with breast cancer
risk in women with ER/PR negative tumors, but none were associated with ER/PR positive
disease (H score > 75; Table 2). Similarly, the P-value for trend associated with increasing
number of variant alleles was statistically significant (P<0.05) for each of these four SNPs in
the ER/PR negative stratum, while no significant associations were observed among ER/PR
positive tumors, despite the approximately equal number of subjects in each category. This
data suggest that the effect of CRY2 on breast cancer risk may be significantly influenced by
the presence of endogenous hormones, and CRY2 may be particularly relevant for ER and
PR negative tumorigenesis. Note that due to sample size limitations, this analysis was
performed for post-menopausal women only.
CRY2 promoter methylation is associated with breast cancer
To determine whether CRY2 promoter methylation was associated with breast cancer risk,
we performed methylation-specific PCR for all patients who had not undergone radio- or
chemotherapy, as well as an equal number of controls frequency matched by age. Although
only untreated cases could be used for methylation analysis, no differences were detected
among several characteristics between untreated and treated cases (Supplementary Table 2).
In both pre- and post-menopausal women, cases had higher methylation indices, although
the difference was only statistically significant among post-menopausal women, where the
mean MI among controls was 22.32% and the mean MI among cases was 30.59% (P=0.049;
Table 3). Although it is unclear how CRY2 promoter methylation influences gene
expression, the fact that cases had a higher degree of methylation in this region implies that
CRY2 may operate as a tumor suppressor.
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Decreased expression of CRY2 in breast tumor tissue, especially in ER/PR positive
cancers
In order to determine whether CRY2 expression is altered in breast tumor samples, we
identified a transcriptional profiling array from the Atlas database which examined gene
expression in breast tumor tissue and adjacent normal breast tissue. As expected based on
our methylation findings, CRY2 levels were significantly lower in tumor tissue (mean
normalized expression=13.4) compared to adjacent normal tissue (mean normalized
expression=77.2; P=0.023; Figure 1). The tissue samples were also categorized according to
their histology (“invasive carcinoma”, “cystic change”, and “normal” tissue), and hormone
receptor status (ER and PR, positive and negative). For each of the histological subgroups,
we also compared CRY2 expression in ER/PR negative tumors, to that in tumors with either
ER or PR expressed. In each case, ER/PR negative tumors had higher CRY2 levels, although
this difference was only statistically significant in the “cystic change” subgroup (mean
CRY2 expression in ER or PR positive samples=52.8, mean CRY2 expression in ER/PR
negative samples=113.1; P=0.027).
Breast cancer relevant transcripts are influenced by CRY2 knockdown in vitro
A whole genome expression microarray revealed several breast cancer-related genes which
displayed significantly altered expression in MCF-7 cells treated with CRY2-targeting
siRNA oligos, relative to cells treated with negative control siRNAs. In order to focus our
analysis on the most highly relevant transcripts, we identified 131 unique breast cancer and
hormone-related transcripts using online resources. Of these, 43 appeared at low intensity in
one or both biological replicates of the microarray, and were thus deemed unreliable
estimates of gene expression, and were excluded from further analysis. 22 of the remaining
88 transcripts (25%) had significantly altered expression following CRY2 knockdown,
representing a variety of biological pathways including regulation of cell differentiation,
proliferation, motility, angiogenesis, and apoptosis, in addition to sex hormone regulation
and estrogen signaling (Table 4). Although it remains unclear why variants in CRY2 might
be especially relevant for ER/PR negative tumors in post-menopausal women, this data
represent an intriguing set of observations which warrant further investigation.
Discussion
Although recent evidence suggests an important role for circadian genes in transcriptional
regulation and cancer-related processes, the extent to which individual genes may serve as
risk or prognostic biomarkers for cancer has yet to be fully elucidated. Together with CRY1
and the Period genes, CRY2 forms the negative arm of the circadian feedback loop, and is
essential for proper maintenance of circadian timing. As such, CRY2 has the potential to
influence, directly or indirectly, the expression and availability of gene products in a variety
of biological pathways (13, 32, 33). The results presented here suggest that variants in CRY2
may significantly influence breast cancer susceptibility, which is consistent with recent
observations from genetic association studies which showed that SNPs in CRY2 are
associated with risk of non-Hodgkin lymphoma (34), and functional genetic variations in
two other circadian genes, PER3 and NPAS2, were significantly associated with breast
cancer risk (35, 36).
An interesting aspect of the epidemiological portion of this study was the impact of
menopausal and hormone receptor status on the association between CRY2 SNPs and breast
cancer risk. Since ER/PR negative tumors are more common among pre-menopausal
women, the implication from these data are that menopausal status is likely a primary
modifier of the gene-disease association, independent from the effects of ER/PR status.
However, the further observation that CRY2 variants were most strongly associated with ER/
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PR negative tumors may be of particular interest for future investigations, given that ER/PR
negative tumors tend to be more aggressive, are not generally treatable with selective
estrogen receptor modulators such as tamoxifen, and are thus associated with decreased
survival (37). While several previous studies have suggested that hormones, including
estrogen, may influence the expression of genes in the circadian system (38–40), the
mechanisms underlying the observed differences in the effect of CRY2 SNPs on breast
cancer risk remain unclear, and warrant further investigation. Of note, we did not have
information on hormone replacement therapy (HRT) use in our population, and were thus
unable to control for it in the analysis. While HRT use is associated with elevated risk of
breast cancer, in order for this exposure to operate as a confounder in our study, it would
have to be associated with CRY2 genotypes. Although this is possible by chance, we feel
that confounding by HRT use is unlikely to explain our results.
Compared to genetic studies of circadian genes in tumorigenesis, epigenetic changes, such
as promoter methylation, remain a relatively unexplored area in the field of cancer research.
The findings from our current study of CRY2 are among the first evidence suggesting that
promoter methylation status in circadian genes could be a potential biomarker for cancer
susceptibility. Our results demonstrate that CRY2 promoter methylation, which may lead to
decreased gene expression, was elevated in breast cancer cases relative to controls. Several
previous studies have also noted significant down-regulation of circadian genes associated
with various cancers. For example, the expression level of several circadian genes, including
CRY2, was significantly diminished among those suffering from chronic myeloid leukemia
compared to healthy individuals (41). Decreased expression of CRY2 was also observed in
hepatocellular carcinomas, and this reduction was not caused by genetic mutations, but by
several factors, including promoter methylation (42). Together, these findings suggest that
methylation changes, in addition to genetic variants in circadian genes, could serve as novel
cancer biomarkers. However, despite these promising initial findings, further study is
needed to confirm this association, as very few cases in our sample were untreated, leaving a
fairly small sample size available for this portion of the study.
Since the methylation analysis was performed using DNA samples isolated from PBLs, it
remains unclear whether epigenetic changes measured in this surrogate tissue are an
accurate reflection of the methylation status in breast tissue. A previous study has
demonstrated strong correlation between methylation in PBLs and colon tissue (kappa
statistic = 86.5%, p < 0.0001) (43), and a large proof-of-principle study found significant
associations between the level of PBL methylation in a number of ER-α target (ERT) genes
and breast cancer risk, highlighting the potential for epigenotyping to be useful in estimating
risk, even when measured in peripheral blood cell DNA (44). If hypermethylation in the
CRY2 promoter region does in fact lead to diminished gene expression, our data indicate that
CRY2 may operate as a tumor suppressor, as increased methylation was associated with
decreased breast cancer risk. This suggestion is corroborated by the transcriptional profiling
array showing that CRY2 expression was lower in tumor tissue than in adjacent normal
tissue. This array also demonstrated that CRY2 was elevated in ER/PR negative breast tissue
samples, which is in keeping with the general suggestion that variants in CRY2 had the
biggest impact on breast cancer risk in women with ER/PR negative tumors.
Among the microarray findings, the strong induction of trefoil factor 1 (TFF1) in cells with
reduced CRY2 (fold change=3.5, Q<0.0001) is of particular interest. TFF1 is strongly
estrogen regulated, and aberrant expression of this transcript can influence a number of
cancer-related pathways, including proliferation, apoptosis, anoikis, angiogenesis, and
migration and invasion (45). In addition, while it has been suggested that TFF1 encourages
cell cycle delay at the G1-S transition, it has also been shown to increase the levels of cyclin
D1 (CCND1), a key stimulator of cell cycle progression (46). Interestingly, CCND1 was
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also significantly induced following CRY2 knockdown (fold change=1.51, Q=0.009). While
the nature of these relationships remains unclear, this data is consistent with the overall
suggestion that CRY2 may have tumor suppressor properties, and provide the intriguing
suggestion that CRY2 may be involved in hormone signaling, with the potential to regulate,
directly or indirectly, transcripts with well-established relevance for breast tumorigenesis.
In summary, our study demonstrates a genetic association of the circadian gene CRY2 with
breast cancer risk, which is potentially modified by menopausal and ER/PR status.
Moreover, an epigenetic association between CRY2 promoter hypermethylation and
increased breast cancer risk was also detected, suggesting that CRY2 may operate as a tumor
suppressor. This role was further supported by an observed decreased expression of CRY2 in
breast tumor tissues and an in vitro loss-of-function analysis, which demonstrated that a
number of breast cancer relevant transcripts displayed altered expression following CRY2
knockdown. These data suggest a novel role for CRY2 in hormone signaling and breast
tumorigenesis, and provide evidence supportive of the hypothesis that the circadian system
may be an important modulator of breast cancer risk. However, additional large studies will
be required in order to further elucidate the role of CRY2 in breast cancer susceptibility.
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Figure 1.
CRY2 expression in breast tissue taken at mastectomy; from a publicly available breast
tumor tissue array. CRY2 expression was compared in paired samples of tumor tissue and
adjacent normal tissue (3–4cm from the tumor boundary) extracted from the same patient. In
addition, CRY2 expression was compared in tissue expressing either ER or PR, versus ER/
PR negative samples from each of three histological subtypes. CRY2 expression was lower
in tumor tissue than in adjacent normal tissue, and ER/PR negative samples had consistently
higher CRY2 levels than those expressing either ER, PR, or both; although this difference
was only statistically significant in the “cystic change” histological subtype.
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